Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):10.1097/QAI.0b013e3182a9215a. doi: 10.1097/QAI.0b013e3182a9215a

Table 4.

Prevalence of respiratory symptoms according to HIV status and PFT results

HIV-infected HIV-uninfected

Respiratory symptom DLCO≤60% DLCO>60% p-value DLCO≤60% DLCO>60% p-value

Usual cough 43% 21% <0.001 26% 18% 0.2
Usual phlegm 42% 28% 0.02 29% 22% 0.3
Wheeze 26% 25% 0.8 29% 23% 0.3
MRC dyspnea≥2 29% 9% <0.001 16% 9% 0.17

FEV1/FVC<0.70 FEV1/FVC≥0.70 p-value FEV1/FVC<0.70 FEV1/FVC≥0.70 p-value

Usual cough 53% 22% <0.001 21% 19% 0.8
Usual phlegm 59% 27% <0.001 20% 25% 0.5
Wheeze 43% 22% 0.001 33% 22% 0.1
MRC dyspnea≥2 31% 11% <0.001 11% 10% 0.7

p-values represent comparisons by PFT strata within HIV-infected or within HIV-uninfected participants.

DLCO results are presented as above or below 60% of predicted normal.

HHS Vulnerability Disclosure